ATLANTA, May 26, 2015 /PRNewswire/ -- EndoChoice today announced the launch of its initial public offering of 6,250,000 shares of its common stock, which will represent 25.6% of its outstanding common stock following its conversion into a Delaware corporation in connection with the offering. The initial public offering price is currently estimated to be between $15 and $17 per share. The underwriters for the offering will also have a 30-day option to purchase up to an additional 937,500 shares of EndoChoice common stock. EndoChoice has applied to list the common stock on the New York Stock Exchange under the symbol "GI".
J.P. Morgan and BofA Merrill Lynch are acting as joint lead book-running managers for the offering. William Blair and Stifel are acting as co-managers for the offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
The offering is being made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone: +1 (866) 803-9204); or BofA Merrill Lynch, Attention: Prospectus Dept., 222 Broadway, New York, NY 10038, or: email@example.com.
Based in the Atlanta, Georgia area, EndoChoice is a medtech company focused on the manufacturing and commercialization of platform technologies including endoscopic imaging systems, devices and infection control products and pathology services for specialists screening, diagnosing and treating a wide range of gastrointestinal conditions, including colon cancer. EndoChoice leverages its direct sales organization to serve more than 2,500 customers in the United States and works with distribution partners in 25 countries. The Company was founded in 2008 and has developed a broad and innovative product portfolio, which includes the Full Spectrum Endoscopy System (Fuse®).
EndoChoice, Fuse, and Full Spectrum Endoscopy are registered trademarks of EndoChoice, Inc.
For more information:
David Gill, Chief Financial Officer